Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic disorders. These naturally occurring molecules are secreted by the gut in response to food intake, stimulating insulin release and suppressing glucagon release. GLP-1 derivatives exhibit promising therapeutic outcomes in treating type